SecBot SecBot
8-K ·Filed Sep 2, 2026

SRXH

SRX Global Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed2mo ago SEC0001493152-26-041250
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

This is a secured debt investment, not an acquisition, so the primary risk for SRXH is credit risk on a pre-revenue biotech. Monitor CERo's clinical trial progress for CER-1236 and its cash burn rate, as the loan matures in ~6 weeks (Oct 15, 2026) unless extended. The secured position and IP collateral provide some downside protection, but the near-term maturity creates a catalyst for either repayment, extension, or potential restructuring.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1.56
T+0 close · Sep 2, 2026 · via day close
Latest settled
+3.21%
T+20 · $1.61 · next T+60 in 8d
Vs SPY
+4.39%
α at T+20
Latest observation
−2.77%
T+55 · FF3 residual α
  1. T+0 · Sep 3 $1.56entry
  2. T+1 · 3mo ago −3.21%α −2.82% · $1.51
  3. T+5 · 2mo ago +1.92%α +3.07% · $1.59
  4. T+20 · 7w ago +3.21%α +4.39% · $1.61
  5. T+55 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SRX Global Inc. (SRXH) entered into a secured debt financing transaction with CERo Therapeutics Holdings, Inc. (CERO), acquiring a Consolidated Senior Secured Promissory Note consolidating $5.67M in prior notes and providing up to $6M in additional advances, for a maximum aggregate loan amount of $11.67M. The loan is secured by a first-priority security interest in all of CERO's assets, including its intellectual property and clinical-stage CER-1236 T-cell therapy program, as well as a pledge of 100% of the subsidiary's stock and an unconditional guaranty from the subsidiary. This is a debt investment by SRXH, not an acquisition, and represents a moderate deployment of capital into a high-risk, pre-revenue biotech company with a near-term maturity date of October 15, 2026, which can be extended by SRXH for up to four 30-day periods at its discretion.

Key Financial Metrics

Deal Value
$11.7M
Deal Type
credit_facility

Key Facts

  • SRX Global acquired a senior secured promissory note from CERo Therapeutics Holdings with an aggregate maximum loan amount of $11,666,108.77.
  • The note consolidates $5,666,108.77 in prior notes and provides for up to $6,000,000 in additional advances, with an initial advance of $775,665.00 funded on August 27, 2026.
  • The loan matures on October 15, 2026, but SRXH can extend the maturity date for up to four consecutive 30-day periods at its discretion.
  • The loan is secured by a first-priority security interest in substantially all assets of CERo Therapeutics, Inc., including key patents and the CER-1236 T-cell therapy program, plus a pledge of 100% of the subsidiary's stock and an unconditional guaranty.
  • The note carries a 10% annual interest rate, increasing to 24.99% upon an event of default.
  • CERo is a clinical-stage biotech with an ongoing Phase 1/1b CERTAIN-T trial for CER-1236 in hematologic malignancies; six patients have been treated with no dose-limiting toxicities observed in the most recent cohort.

Financial Impact

SRXH deployed $775,665 in initial cash and has committed up to $11.67M total in secured debt to CERo, a pre-revenue biotech. The investment yields 10% annual interest and is secured by CERo's IP and assets.

debtinterest_incomecash_flow

Risk Factors

  • CERo is a pre-revenue clinical-stage biotech with no approved products, carrying high execution and financing risk.
  • The loan matures on October 15, 2026, creating near-term liquidity pressure on CERo; if CERo cannot repay, SRXH may need to extend or exercise remedies against collateral.
  • The value of the collateral (IP, clinical-stage assets) is highly uncertain and dependent on clinical trial outcomes and regulatory approval.

Market Snapshot

Exchange
NYSE
Sector
Beverages
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Consumer & Retail

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-041250
Exhibit: ex10-2.htm0001493152-26-041250
Exhibit: ex10-3.htm0001493152-26-041250
Exhibit: ex10-4.htm0001493152-26-041250
Exhibit: ex99-1.htm0001493152-26-041250
Document: form8-k.htm0001493152-26-041250
Document: 0001493152-26-041250-index-headers.html0001493152-26-041250
Document: 0001493152-26-041250-index.html0001493152-26-041250
Document: 0001493152-26-041250.txt0001493152-26-041250

Track record

30 reports on SRXH

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.11% at T+60 after the Jun 18, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 20, 20261d ago Press Release Neutral 3/10 Entry $0.8402 Now $0.8000 −4.78% settles Nov 30
  2. Nov 20, 20261d ago SC 13D Neutral 5/10 Entry $0.9950 Now $0.8000 −19.60% settles Nov 30
  3. Oct 30, 202622d ago Press Release Neutral 3/10 Entry $1.01 to $0.8116 Now $0.8000 −20.79% ▼ −19.64% −16.94% vs SPY
  4. Oct 7, 20266w ago 8-K Mixed 6/10 Entry $1.49 to $1.29 Now $0.8000 −46.31% ▼ −13.42% −12.44% vs SPY
  5. Oct 6, 20266w ago 8-K Neutral 4/10 Entry $1.49 to $1.29 Now $0.8000 −46.31% ▼ −13.42% −12.44% vs SPY
  6. Sep 24, 20268w ago Press Release Neutral 3/10 Entry $1.73 to $1.61 Now $0.8000 −53.76% ▼ −6.94% −6.52% vs SPY
  7. Sep 9, 202610w ago 8-K Neutral 3/10 Entry $1.51 to $1.60 Now $0.8000 −47.02% ▲ +5.96% +6.62% vs SPY
  8. Sep 2, 202611w ago 8-K Neutral 5/10 Viewing Entry $1.56 to $1.59 Now $0.8000 −48.72% ▲ +1.92% +3.07% vs SPY
  9. Aug 28, 202612w ago 8-K Bearish 5/10 Entry $1.68 to $1.59 Now $0.8000 +52.38% ▲ +5.65% +5.51% vs SPY
  10. Aug 19, 202613w ago 8-K Mixed 5/10 Entry $1.87 to $1.84 Now $0.8000 −57.22% ▼ −1.60% −1.22% vs SPY
Showing 10 of 30

US Market Status

Market Closed · Opens Mon (26h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 2, 2026